Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Danaher (DHR) and BridgeBio Pharma (BBIO)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Danaher (DHR – Research Report) and BridgeBio Pharma (BBIO – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sarepta Therapeutics (SRPT)
In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Sarepta Therapeutics, with a price target of $20.00. The company’s shares closed last Friday at $20.34.
According to TipRanks.com, Ulz is a 3-star analyst with an average return of
Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $22.13, implying a 5.1% upside from current levels. In a report issued on January 20, Evercore ISI also maintained a Hold rating on the stock with a $17.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Danaher (DHR)
Morgan Stanley analyst Kallum Titchmarsh maintained a Buy rating on Danaher today and set a price target of $270.00. The company’s shares closed last Friday at $218.89.
According to TipRanks.com, Titchmarsh is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Danaher with a $266.18 average price target, representing a 21.3% upside. In a report issued on January 28, TipRanks – DeepSeek also upgraded the stock to Buy with a $263.00 price target.
BridgeBio Pharma (BBIO)
Morgan Stanley analyst Sean Laaman maintained a Buy rating on BridgeBio Pharma today and set a price target of $96.00. The company’s shares closed last Friday at $77.27.
According to TipRanks.com, Laaman is a 5-star analyst with an average return of
Currently, the analyst consensus on BridgeBio Pharma is a Strong Buy with an average price target of $94.79, implying a 20.2% upside from current levels. In a report issued on January 27, Barclays also initiated coverage with a Buy rating on the stock with a $157.00 price target.
